ViroGen is a veterinary biopharmaceutical company

ViroGen is developing 2nd and 3rd generation animal vaccines for the control of poultry diseases.

ViroGen specializes in novel, proprietary in ovo (embryo) vaccination technology for the poultry industry

In ovo vaccination technology involves injecting vaccine into eggs at the later stages of embryonation, prior to hatching.

ViroGen has produced and is commercializing a unique Newcastle vaccine called New ovo-mune

The New ovo-mune vaccine will protect chickens against Newcastle disease.

A Note from Our CEO

Paul Hogan, CEO of ViroGen, Inc., notes that "Every production bird in the world is required to be vaccinated, and since ViroGen's vaccine is breakthrough technology and the most effective in ovo patent-protected product on the market, the company anticipates it will capture this exclusive market for several years. VRGI has prepared for rapid expansion into this worldwide market of approximately 45 billion birds annually (85% of the world market) by establishing a distributor network prior to licensing. With a growth rate of 30% per year and growing, one can anticipate the revenue opportunity for this vaccine is in the tens of millions."